All News
Iterum Therapeutics will head back into the clinic to meet regulatory requirements to refile a New Drug Application for oral sulopenem.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative trend vote on the company’s Marketing Authorization Application for Aduhelm.
While COVID-19 appears to be surging again in the U.S. and Europe, the government is spending billions to acquire antibody and antiviral therapies and edging toward vaccination boosters.
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
Pfizer is initiating an external search for a new CFO with Frank D’Amelio agreeing to remain with the company through the transition.
Investors are falling in with these biotech companies, dropping dollars to fuel their work for the latest advancement in life sciences.
Chroma Medicine debuted Wednesday morning with $125 million in seed and Series A funding.
Earlier studies suggest a correlation between COVID-19 vaccines and menstrual changes. A new study says otherwise.
AcelRx Pharmaceuticals and Kala Pharmaceuticals both shared acquisition news on Monday. Here’s a closer look at each of the acquisition announcements.
After 32 years, gene therapy pioneer Guangping Gao, Ph.D., is finally seeing the fruits of the doctoral thesis research he started in 1989.
Scientists from Brigham and Women’s Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer’s disease.
Three companies have posted major developments in the field of heart disease therapy.
Pfizer’s oral antiviral treatment for COVID-19 is making its way through regulatory hurdles. The company is working with global manufacturers to ensure a steady supply of the medication.
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
Researchers have published a study of a woman being called the “Esperanza patient,” one of what researchers call “elite controllers,” who seem to eradicate HIV naturally.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Biogen announced that after 23 years with the company, Alfred W. Sandrock Jr. will retire on Dec. 31. Sandrock had his hand in the development of multiple treatments for neurological diseases.
Los Angeles-based ACELYRIN, Inc. announced a quarter-million dollars in Series B financing Tuesday morning, along with a splashy licensing deal.
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Flagship Pioneering Founder and CEO Noubar Afeyan has been behind the launch of dozens of companies, some of which, such as Moderna, have become a household name across the globe.